[KLOW Formulation Notes](/) / formulation

# A KLOW peptide preparation needs more than a list

Knowing the ingredients leaves two practical questions open: how the mixture holds up, and whether it fits a person.

![The open red door of an outdoor kiln with cream bowls visible in its shaded interior](/klow-kiln-20a193edf93a/open-kiln-hinge.webp)

## Which ingredients

KLOW adds KPV to a mixture of BPC-157, GHK-Cu and TB-500. These stay separate chemical substances, without becoming one new molecule. Their names alone cannot verify a particular preparation.

## How they behave together

Compatibility means how ingredients behave when mixed. GHK-Cu carries copper, which raises a theoretical chemistry question for this blend. That question hasn’t been formally settled; it isn’t evidence of a failed preparation.

## How they hold up

Stability means how a preparation holds up over time. Separate ingredient studies cannot establish the finished mixture’s storage life. They also cannot supply handling instructions for an individual medicine.

## Who is being assessed

A prescription review considers a person’s history, current care and reason for seeking treatment. The ingredient list cannot do that job. A clinician may decide the preparation is unsuitable.

## The name leaves the practical work to do

KLOW is a blend name, with no FDA-approved combination product setting its formula. I want the actual preparation explained: what is in it, what supports combining it, and what supports the proposed use. A familiar name cannot answer all three.

Promise Peptides offers compounded KLOW peptide at mypromise.com. When a request arrives, a licensed U.S. clinician handles the individual review and decides whether to prescribe; some patients may not qualify. The service takes U.S. patients only; where they live and the proposed treatment can further limit access. These compounded medicines have no FDA approval.

### A prescription does not change approval status

[FDA explains why medicines are compounded](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) for needs that an approved product may not meet. Compounded medicines remain unapproved by FDA. The agency hasn’t checked that preparation’s safety, effectiveness and quality through its approval process before marketing.

The safety page’s April 22, 2026 date describes its content, not when individual entries moved. Its [table of withdrawn nominations](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) names BPC-157, KPV and TB-500; the GHK-Cu entry covers injectable routes specifically. The entries no longer appear in Category 2. The page supplies no date for an individual move. The nominations were withdrawn, not cleared: safety warnings remain, without an approval for compounding.

### Location is part of access

The [medical boards’ telemedicine policy](https://www.fsmb.org/siteassets/advocacy/policies/fsmb-workgroup-on-telemedicineapril-2022-final.pdf) discusses a clinician’s authority where the patient is located. It is a model policy; actual state rules and exceptions govern an appointment. Availability can vary by state and treatment, even when a listing is visible online.

Questions for a review can be concrete: who would prepare the medicine, what supports this exact mixture and route, and how would quality and follow-up be handled? A different plan or no prescription remains possible. The [dosage discussion](/dosage) explains why an ingredient amount cannot fill the evidence gap.

---

KLOW Formulation Notes is a reading guide for curious people; it offers no clinical care, pharmacy services or products.

© 2026 KLOW Formulation Notes.

[Home](/) · [Dosage](/dosage) · [Effects](/effects) · [Research](/research) · [Vs Wolverine](/vs-wolverine) · [Formulation](/formulation) · [References](/references) · [Results](/results) · [About](/about) · [Contact](/contact)